Chong Kun Dang Pharmaceutical Corp.
🇰🇷South Korea
- Country
- 🇰🇷South Korea
- Ownership
- Public
- Established
- 1941-01-01
- Employees
- 2.3K
- Market Cap
- -
- Website
- http://www.ckdpharm.com
A Study Evaluating the Efficacy and Safety of CKD-314 (Nafabelltan) in Hospitalized Adult Patients Diagnosed With COVID-19 Pneumonia
- First Posted Date
- 2020-11-10
- Last Posted Date
- 2021-02-02
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 104
- Registration Number
- NCT04623021
- Locations
- 🇷🇺
A108_02CVD2014 Site# 29, St. Petersburg, Russian Federation
🇷🇺A108_02CVD2014 Site# 3, St. Petersburg, Russian Federation
🇷🇺A108_02CVD2014 Site# 31, Ryazan, Russian Federation
Clinical Study to Evaluate the Pharmacokinetic Profiles and Safety of CKD-333 Low Dose in Healthy Volunteers
Phase 1
- Conditions
- Cardiovascular Disease
- Interventions
- Drug: CKD-330 Tab. and D090 Tab.Drug: CKD-333 Tab.
- First Posted Date
- 2020-11-02
- Last Posted Date
- 2020-11-02
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 51
- Registration Number
- NCT04611932
- Locations
- 🇰🇷
Chonbuk National University Hospital, Jeonju, Korea, Republic of
A Clinical Trial to Evaluate the Pharmacokinetics and Tolerability of CKD-348
Phase 1
Completed
- Conditions
- Hypertension and Dyslipidemia
- Interventions
- Drug: CKD-828, D097, D337
- First Posted Date
- 2020-10-14
- Last Posted Date
- 2021-02-04
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 62
- Registration Number
- NCT04587206
- Locations
- 🇰🇷
H Plus Yangji Hospital, Seoul, Gwanak-gu, Korea, Republic of
Study to Evaluate the Efficacy and Safety of CKD-352
- First Posted Date
- 2020-09-14
- Last Posted Date
- 2021-06-01
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 283
- Registration Number
- NCT04548427
- Locations
- 🇰🇷
Pusan National University Hospital, Pusan, Korea, Republic of
Clinical Trial to Evaluate the Efficacy and Safety of TenofoBell® Tablet in Chronic Hepatitis B Patients
Phase 4
Completed
- Conditions
- Chronic Hepatitis B
- Interventions
- Drug: Experimental
- First Posted Date
- 2020-09-07
- Last Posted Date
- 2021-07-28
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 78
- Registration Number
- NCT04539652
- Locations
- 🇰🇷
Daegu Chatholic University Medical center, Daegu, Korea, Republic of
A Clinical Trial to Evaluate the Blood Pressure Lowering Effect of a Candemore Plus Tab Versus Cantabell Tab in Hypertensive Patients Inadequately Controlled by Candesartan Monotherapy
Phase 4
Completed
- Conditions
- Hypertension
- Interventions
- Drug: Cantabell TabDrug: Candemore Plus Tab
- First Posted Date
- 2020-08-20
- Last Posted Date
- 2020-08-20
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 132
- Registration Number
- NCT04521023
- Locations
- 🇰🇷
Ajou University Hospital, Suwon, Gyeonggi-do, Korea, Republic of
🇰🇷Jeju National University Hospital, Jeju, Korea, Republic of
🇰🇷Daegu Catholic Univ. Medical Center, Daegu, Korea, Republic of
Clinical Trial to to Compare of the Efficacy and Safety of Lipilou® 20 mg and Lipilou® 10 mg
Phase 4
Completed
- Conditions
- Hypercholesterolemia
- Interventions
- Drug: Lipilou®(generic atorvastatin drug) 20 mgDrug: Lipilou®(generic atorvastatin drug) 10 mg
- First Posted Date
- 2020-08-12
- Last Posted Date
- 2020-08-12
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 250
- Registration Number
- NCT04511000
- Locations
- 🇰🇷
Korea University Ansan Hospital, Ansan, Korea, Republic of
🇰🇷Dong-A University Hospital, Busan, Korea, Republic of
🇰🇷Sejong General Hospital, Bucheon, Korea, Republic of
Evaluation of the Safety and Tolerability of CKD-508 in Healthy Subjects
Phase 1
Completed
- Conditions
- Healthy Subjects
- Interventions
- Drug: CKD-508 TabletDrug: Placebo TabletDrug: Placebo CapsuleDrug: CKD-508 Capsule
- First Posted Date
- 2020-07-28
- Last Posted Date
- 2024-02-15
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 88
- Registration Number
- NCT04488900
- Locations
- 🇬🇧
Northwick Park Hospital, Harrow, Middlesex, United Kingdom
Clinical Trial to Evaluate the Safety and Pharmacokinetic Characteristics in Healthy Volunteers
Phase 1
- Conditions
- Cardiovascular Disease
- Interventions
- Drug: CKD-330 Tab. and D086 Tab.Drug: CKD-333 Tab.
- First Posted Date
- 2020-07-20
- Last Posted Date
- 2020-07-22
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 51
- Registration Number
- NCT04478097
- Locations
- 🇰🇷
Jang Hee Hong, Daejeon, Korea, Republic of
Efficacy and Safety of Everolimus Versus Mycophenolate Mofetil in Liver Transplant Recipients.
Phase 4
- Conditions
- Liver Transplant
- Interventions
- First Posted Date
- 2020-07-15
- Last Posted Date
- 2020-07-15
- Lead Sponsor
- Chong Kun Dang Pharmaceutical
- Target Recruit Count
- 150
- Registration Number
- NCT04471441
- Locations
- 🇰🇷
Severance Hospital, Seoul, Korea, Republic of
© Copyright 2025. All Rights Reserved by MedPath